Table 2.
Regimens of the triple combination therapy.
| Treatment | No. (%) | |
|---|---|---|
| HAIC regimen | FOLFOX | 113 (77.9) |
| RALOX | 32 (22.1) | |
| TKI+PD-1 regimen | Lenvatinib+Camrelizumab | 91 (62.8) |
| Lenvatinib+ Stintilimab | 16 (11.0) | |
| Lenvatinib+ Tislelizumab | 6 (4.1) | |
| Sorafenib+ Camrelizumab | 19 (13.1) | |
| Sorafenib+ Stintilimab | 4 (2.8) | |
| Apatinib+ Camrelizumab | 9 (6.2) | |
| HAIC treatment cycle | ||
| Median (range) | 3 (1-6) | |
| PD-1 treatment cycle | ||
| Median (range) | 4 (1-10) |
HAIC, hepatic arterial infusion chemotherapy; FOLFOX, HAIC with oxaliplatin, 5-fluorouracil, and leucovorin; RALOX, HAIC with raltitrexed plus oxaliplatin; TKIs, tyrosine kinase inhibitors; PD-1, programmed cell death protein-1.